Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.

Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications. 

Register Now

Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.

Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.

Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

2024 issues

With eGFR in EHR, stronger clinical decision support

November 2024—In health care, information overload is hardly a novel problem. But when it comes to overlooking impaired kidney function in the electronic health record, Children’s Mercy Kansas City found a novel fix—at least for a pediatric institution. The solution, says Darcy Weidemann, MD, MHS, pediatric nephrologist at Children’s Mercy Kansas City and associate professor, University of Missouri-Kansas City School of Medicine, was to implement estimated glomerular filtration rate in the EHR.

Inside new edition of gyn cytopathology guide

November 2024—New this month from CAP Publications is the CAP Practical Guide to Gynecologic Cytopathology—Morphology, Management, and Molecular Methods, second edition. Its 15 chapters cover squamous and glandular epithelial abnormalities, anal cytology, benign changes and mimics of premalignant and malignant epithelial lesions, and much more. In this issue we provide part of the chapter on look-alikes and morphologic spectrums of change.

AMP case report: Molecular insights into the bi-clonal presence of inversion 16 and Philadelphia chromosome in relapsed post-treatment acute myeloid leukemia

November 2024—Acute myeloid leukemia (AML) stands out as the most prevalent form of leukemia, constituting 80 percent of cases in adults and 15 to 20 percent in children. It arises from the clonal proliferation of genetically aberrant hematopoietic stem and progenitor cells, impeding normal hematopoiesis. AML is linked to a variable number of cytogenetic abnormalities, and the identification of these abnormalities holds crucial implications, given their association with an elevated risk of inherited AML.

LIS experts on HL7, AI, home-test results, and more

Lab data displays, IT demands that outrun resources, at-home test results, and HL7 are some of what came up on Sept. 20 when CAP TODAY publisher Bob McGonnagle spoke online with pathologists and industry executives about laboratory information systems. “It’s fire and forget,” said Ulysses G. J. Balis, MD, of the University of Michigan, about the lack of feedback from the EHR that a clinician has seen and understood a complex result. “Loss to follow-up is a real possibility,” he said.

Surveying cancer protocol use far and wide

November 2024—Members of the CAP Foundation Global Pathology Committee and the CAP Cancer Committee collaborated to develop a three-part webinar series on how to use the CAP cancer protocols. The webinars were directed to international pathologists, particularly those in low- and middle-income countries.

From the President’s Desk

November 2024—There’s a shortage of physicians in the U.S.—across specialty areas and including pathology—and the reaction has been rather predictable: nonphysicians are pushing hard to fill those voids. Scope of practice is a major issue facing physicians today, and pathologists are no exception. In other specialties, we’ve seen nurse practitioners and physician assistants step up to take on more and more responsibilities that were once reserved for physicians. For certain tasks and under the supervision of a physician, this is not only appropriate but welcome. In pathology we have pathologist assistants performing valuable tasks in support of pathologists with a real impact on patient care. All of these nonphysicians are important for patient care and for easing the burden on physicians who are stretched too thin.

Clinical pathology selected abstracts

November 2024—Pathology training programs are meant to prepare trainees for the workforce by imparting medical knowledge and developing skills in diagnostic interpretation in anatomic pathology. Yet transitioning to the workforce can be challenging for some new graduates. To address this, many training programs have begun teaching management and leadership skills that are required on the job. In addition, the College of American Pathologists New in Practice Committee developed online educational material to provide practical advice for those starting their pathology careers.

Anatomic pathology selected abstracts

November 2024—Inactivating alterations in switch/sucrose nonfermentable (SWI/SNF) chromatin remodeling complex subunits have been described in multiple tumor types. Recent studies focused on SMARC subunits of this complex to explain their relationship with tumor characteristics and therapeutic opportunities. Pancreatic cancer with these alterations has not been well studied, although isolated cases of undifferentiated carcinomas have been reported.

Molecular pathology selected abstracts

November 2024—Many people with an intellectual disability do not receive a molecular diagnosis following genetic testing. While 1,427 genes have been confidently identified as etiological for an intellectual disability (ID), all but nine of them are protein coding. To identify noncoding etiologies of ID, the authors conducted a genetic association analysis using whole genome sequencing data on 77,539 participants in the 100,000 Genomes Project. The study included 29,741 probands and 4,782 affected relatives assigned by expert clinicians to one or more of 220 specific disease classes encompassing a wide range of pathologies.

Q&A column

NOVEMBER 2024 Q. Our laboratory was cited for a deficiency because the manufacturer and methodology of our tumor marker assay was not available to clinicians. What is the reasoning behind this requirement? Read answer.
Q. For patients who have a hematocrit level greater than 55 percent, is it okay to use a CBC (hematocrit) that was not collected at the same time as the citrate sample? For example, can we use a CBC collected within 24 hours for an inpatient and a CBC from a previous visit for an outpatient? Read answer.

MARKETPLACE

TRENDING